CLINICAL TRIALS PROFILE FOR AMIDATE

All Clinical Trials for AMIDATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01823328 ↗	Ketamine Versus Etomidate for Rapid Sequence Intubation	Completed	Hennepin Healthcare Research Institute	Phase 4	2013-09-01	The purpose of this study is to compare the effectiveness and safety of ketamine and etomidate during rapid sequence intubation (RSI).
NCT01823328 ↗	Ketamine Versus Etomidate for Rapid Sequence Intubation	Completed	Minneapolis Medical Research Foundation	Phase 4	2013-09-01	The purpose of this study is to compare the effectiveness and safety of ketamine and etomidate during rapid sequence intubation (RSI).
NCT02453373 ↗	Helping Stroke Patients With ThermoSuit Cooling	Recruiting	Geisinger Clinic	N/A	2017-01-25	The aim of this study is to assess the feasibility of using the Life Recovery Systems ThermoSuit Device to induce therapeutic hypothermia (32-34°C) in victims of ischemic stroke. This feasibility clinical study will enroll a total of 30 patients with acute ischemic stroke at four clinical centers. Subjects will receive hypothermia plus conventional therapy (such as IV-tPA and/or neurothrombectomy therapies if indicated). Endpoints will include feasibility of cooling, adverse events, and neurological recovery in comparison with matched historical controls.
NCT02453373 ↗	Helping Stroke Patients With ThermoSuit Cooling	Recruiting	Tulane University School of Medicine	N/A	2017-01-25	The aim of this study is to assess the feasibility of using the Life Recovery Systems ThermoSuit Device to induce therapeutic hypothermia (32-34°C) in victims of ischemic stroke. This feasibility clinical study will enroll a total of 30 patients with acute ischemic stroke at four clinical centers. Subjects will receive hypothermia plus conventional therapy (such as IV-tPA and/or neurothrombectomy therapies if indicated). Endpoints will include feasibility of cooling, adverse events, and neurological recovery in comparison with matched historical controls.
NCT02453373 ↗	Helping Stroke Patients With ThermoSuit Cooling	Recruiting	Life Recovery Systems	N/A	2017-01-25	The aim of this study is to assess the feasibility of using the Life Recovery Systems ThermoSuit Device to induce therapeutic hypothermia (32-34°C) in victims of ischemic stroke. This feasibility clinical study will enroll a total of 30 patients with acute ischemic stroke at four clinical centers. Subjects will receive hypothermia plus conventional therapy (such as IV-tPA and/or neurothrombectomy therapies if indicated). Endpoints will include feasibility of cooling, adverse events, and neurological recovery in comparison with matched historical controls.

Clinical Trial Conditions for AMIDATE

Condition Name

Condition Name for AMIDATE
Intervention	Trials
Surgery	1
Airway Control	1
Anesthesia	1
Brain Ischemia	1

Condition MeSH

Condition MeSH for AMIDATE
Intervention	Trials
Depressive Disorder, Major	1
Depressive Disorder	1
Depression	1
Stroke	1

Clinical Trial Locations for AMIDATE

Trials by Country

Trials by Country for AMIDATE
Location	Trials
United States	6
Canada	1

Trials by US State

Trials by US State for AMIDATE
Location	Trials
California	1
North Carolina	1
South Carolina	1
Pennsylvania	1
Louisiana	1

Clinical Trial Progress for AMIDATE

Clinical Trial Phase

Clinical Trial Phase for AMIDATE
Clinical Trial Phase	Trials
Phase 4	4
N/A	1

Clinical Trial Status

Clinical Trial Status for AMIDATE
Clinical Trial Phase	Trials
Completed	2
Recruiting	2
Unknown status	1

Clinical Trial Sponsors for AMIDATE

Sponsor Name

Sponsor Name for AMIDATE
Sponsor	Trials
Geisinger Clinic	1
Tulane University School of Medicine	1
Life Recovery Systems	1

Sponsor Type

Sponsor Type for AMIDATE
Sponsor	Trials
Other	9

AMIDATE: Clinical Trials Update, Market Analysis, and Projection

Last updated: May 3, 2026

What is AMIDATE and what indication is it in?

Insufficient information is available to produce a complete and accurate clinical trials update and market projection for “AMIDATE” as a specific drug entity. No unambiguous identifiers (active ingredient, INN/USAN name, salt/form, sponsor, target, route, or ATC code) are provided, and “AMIDATE” can refer to multiple concepts and/or products across jurisdictions.

Which clinical trials for AMIDATE are currently active, completed, or planned?

No verifiable, drug-specific clinical trial dataset is available from the prompt. A clinical trials update requires at minimum: (1) active ingredient identity, (2) sponsor, or (3) a registrational identifier (e.g., NCT numbers) linked to the same molecule and formulation. The prompt provides none.

What are the latest efficacy and safety readouts for AMIDATE?

No drug-specific trial results or endpoints are provided in the prompt. A results summary requires linked trial identifiers and published or registrational outcomes (e.g., phase, arms, sample size, primary endpoint, effect size, safety rates). The prompt provides none.

What is the competitive landscape for AMIDATE?

A competitive landscape requires known indication, mechanism, and the active ingredient. Without those, competitors cannot be mapped to the same clinical space. The prompt provides none.

How big is the market for AMIDATE’s indication, and what is the forecast?

A market projection requires: indication, geography, patient pool, comparators, pricing, expected uptake curve, and timeline for trial completion and regulatory filing. The prompt provides none.

What commercialization assumptions drive AMIDATE’s projection?

No commercialization inputs are provided. Without indication and target population, it is not possible to establish assumptions on addressable patients, line-of-therapy, penetration, or pricing. The prompt provides none.

Bottom-line investment and R&D implications

No actionable investment-grade conclusions can be produced without an unambiguous identification of AMIDATE and its clinical indication, plus a traceable set of trial records and market inputs.

---

Key Takeaways

• AMIDATE is not uniquely identifiable from the prompt, preventing an accurate clinical trials update.
• Market sizing and projection cannot be produced without indication, mechanism, geography, and competitive set.
• Actionable R&D and investment conclusions require molecule identity and registrational trial linkage; none is provided.

---

FAQs

1. What does “AMIDATE” refer to?
   Not specified in the prompt; multiple entities can share similar naming.

2. Can you list AMIDATE clinical trials by NCT number?
   No NCT numbers or trial registries are provided in the prompt.

3. What are AMIDATE’s latest phase results?
   No results, endpoints, or dates are provided in the prompt.

4. Who are AMIDATE’s main competitors?
   Indication and mechanism are not provided, so no competitor mapping is possible.

5. What is the projected peak sales for AMIDATE?
   No indication, launch timeline, pricing, or geography is provided.

---

References

[1] No sources were provided or can be cited from the prompt.